Overview

Perioperative Analgesia for Knee Arthroplasty (PAKA)

Status:
Completed

Trial end date:
2011-07-01

Target enrollment:
0

Participant gender:
All

Summary

Peri-articular knee infiltration with Levobupivicaine 150mg, Morphine 10mg and Ketorolac 30mg reduces postoperative pain following primary total knee replacement compared with the current standard treatment of femoral nerve blockade.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Warwick

Treatments:

Epinephrine
Epinephryl borate
Ketorolac
Ketorolac Tromethamine
Levobupivacaine
Morphine
Racepinephrine

Criteria

Inclusion Criteria:

- All patients undergoing an elective primary unilateral total knee arthroplasty (TKA)
under the care of an orthopaedic consultant at University Hospitals Coventry and
Warwickshire NHS trust are potentially eligible for the trial.

Exclusion Criteria:

- Those with sufficient cognitive impairment that they would be unable complete
questionnaire (cognitive impairment).

- Those patients who lack capacity under the Mental Capacity Act 2005

- Those patients with a pre-operative history of neurological abnormality in the
ipsilateral leg e.g. history of stroke, neurogenic pain or previous nerve injury.

- Those patients having spinal anaesthesia.

- Those patients with a specific contraindication to the analgesic agents used:Morphine:
Hypersensitivity reaction Ketorolac: Active or previous peptic ulcer. History of upper
gastrointestinal bleeding or perforation, related to previous NSAID therapy.

- Haemorrhagic diatheses, including coagulation disorders

- Hypersensitivity to ketorolac trometamol or other NSAIDs

- Moderate or severe renal impairment (serum creatinine > 160 micromol/l)

- Levobupivicaine: Levobupivacaine solutions are contra-indicated in patients with a
known hypersensitivity to levobupivacaine, local anaesthetics of the amide type or any
of the excipients

- Uncontrolled angina

- 2nd/ 3rd degree heart block